IQV
IQVIA Holdings Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$266.63
−1.84%Year over year
Reported trailing growth
- Revenue
- +8.2%
- EBITDA
- +5.3%
- EBIT
- +5.8%
- EPS
- +16.5%
- Free cash flow
- +30.0%
- Operating cash flow
- +7.7%
Forward estimates
Based on analyst estimates
- Revenue
- +5.5%
- EBITDA
- +30.1%
- EPS
- +67.4%
Three-year CAGR
- Revenue
- +4.2%
- EBITDA
- +6.0%
- EBIT
- +8.3%
- Net income
- +7.6%
- EPS
- +10.8%
- Free cash flow
- +8.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026